Indian Patient Experience on Adalimumab

Speciality: Rheumatology


Speaker:

Dr. Sumeet Agrawal - Moderator | Head of Rheumatology and Clinical Immunology,

Dr. Himanshu Aggarwal - Speaker | Consultant Rheumatologist

Dr. Puneet Srivastava - Speaker | Senior Consultant Rheumatologist

Dr. Shubha Bhalla - Speaker | Consultant Rheumatologist

Description:

A warm welcome to all the medical professionals in this interesting session on Indian Patient Experience on Adalimumab
Adalimumab, a widely used biologic for treating various autoimmune conditions, has garnered positive feedback from Indian patients for its efficacy in managing diseases such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Patients report significant improvements in symptom relief, including reduced pain, swelling, and skin lesions, leading to enhanced quality of life. This biologic’s ability to provide rapid and sustained symptom control has been particularly appreciated, allowing patients to regain mobility and participate more actively in daily activities.
However, the high cost of adalimumab remains a significant barrier for many Indian patients, limiting its accessibility despite its proven benefits. To address this issue, the introduction of biosimilars has provided a more affordable alternative, increasing the number of patients who can benefit from this treatment. Patients using biosimilar versions have reported similar therapeutic outcomes, making these options a valuable addition to the treatment landscape in India.
Therefore, get an overall knowledge of indian patient experience on adalimumab
 

See More Webinars @ Hidoc Webinars





Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Parents, teachers at Missouri school want answers after string of cancer diagnoses

2.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma

3.

Survival improved with lobectomy, segmentectomy in early non-small cell lung cancer

4.

Prostate cancer 'is not a death knell': Early detection and personalized care improve outcomes, study shows

5.

Two medications might work better for breast cancers that are resistant to one.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot